Media releases

Roche medicine Avastin receives EU approval for the treatment of women with newly diagnosed, advanced ovarian cancer

Avastin represents first major treatment advance for women with ovarian cancer in 15 years. Roche announced today that the European Commission has approved Avastin (bevacizumab) in combination with ...

Roche's personalized medicine Zelboraf receives positive opinion from European authority for the treatment of people with BRAF mutation-positive metastatic melanoma

Roche, today announced that the Committee for Medicinal Products for Human Use (CHMP) has recommended that Zelboraf be granted full marketing authorization as a monotherapy for the treatment of adult ...

Changes to the Roche Corporate Executive Committee

Roche today announced that Sophie Kornowski-Bonnet, currently General Manager of Roche Pharma in France, has been appointed Head of Roche Partnering. Sophie Kornowski-Bonnet will assume her new role ...

Roche announces positive results of pivotal Phase III study with pertuzumab in HER2-positive metastatic breast cancer

Roche today announced results from CLEOPATRA, the first randomised Phase III study of the investigational HER2-targeted medicine pertuzumab. The study compared the combination of pertuzumab, ...

Roche establishes external Academic Translational Centre in Zurich

Roche, together with ETH Zurich (Swiss Federal Institute of Technology, Zurich), the University of Zurich (UZH) and the University Hospital Zurich (USZ) announced today the formation of an external ...

Roche establishes external Academic Translational Centre in Zurich

Roche acquires Verum Diagnostica GmbH to strengthen portfolio in coagulation diagnostics

Roche announced today that it has signed an agreement under which it will acquire 100 percent of Verum Diagnostica GmbH, based in Munich, Germany. Verum Diagnostica is a leading company in ...

Roche's cobas EGFR Mutation Test For Personalized Treatment Of Non-Small Cell Lung Cancer Receives CE Mark

New Test allows identification of lung cancer patients who may benefit from early treatment with EGFR inhibitors. Roche announced today that the cobas EGFR Mutation Test is now CE marked for ...

Roche to present important new data for HER2-positive breast cancer at 2011 San Antonio Breast Cancer Symposium

Roche today announced that it will present results from studies of its investigational medicine pertuzumab in HER2-positive breast cancer, at the 34th Annual CTRC-AACR San Antonio Breast Cancer ...

Roche signs agreement with PTC Therapeutics to advance treatment for Spinal Muscular Atrophy (SMA)

Collaboration offers new hope for a potential treatment for the leading genetic cause of death in infants and toddlers

Roche signs agreement with PTC Therapeutics to advance treatment for Spinal Muscular Atrophy (SMA)

Roche NimbleGen and BGI Develop Advanced MHC Region Capture Technology for Human Disease and Biomedical Research

Roche NimbleGen, Inc. and BGI, the world’s largest genomic organization, announced that they have developed a Major Histocompatibility Complex (MHC) region capture technology based on NimbleGen ...

FDA Commissioner Announces Final Decision on Avastin for Metastatic Breast Cancer

U.S. Food and Drug Administration (FDA) Commissioner revokes approval of Avastin for treatment of metastatic breast cancer (mBC) in the United States. This action concludes the FDA’s review of ...

FDA accepts Roche's New Drug Application for vismodegib in advanced form of skin cancer

Roche today announced that the U.S. Food and Drug Administration (FDA) has accepted and filed the company’s New Drug Application for vismodegib for the treatment of adults with advanced basal cell ...

Roche announces commercial availability of the new Elecsys PTH (1–84) assay

Fully automated assay provides accurate assessment of parathyroid function in patients with chronic kidney disease in routine clinical practice. Roche announces the market availability of the Elecsys ...

New study correlates sFlt-1/PIGF with disease severity in PE/HELLP Patients with a high sFlt-1/PIGF ratio show significantly increased risk for imminent delivery

A new study now published in the American Journal of Obstetrics and Gynecology1 shows the ratio of angiogenic factors, soluble fms-like tyrosine kinase-1 (sFlt-1) and placental growth factor (PIGF). ...

NT-proBNP–guided therapy reduces cardiovascular event rates and improved quality of life in heart failure patients

Positive study results promote a new paradigm in the management of heart failure. In the recently published PROTECT (Pro-BNP Outpatient Tailored Chronic HF Therapy) trial, a strategy of NT-proBNP ...

Phase II study showed ocrelizumab maintained significant reduction in disease activity for multiple sclerosis patients for almost two years

Phase III trials underway to investigate ocrelizumab in two forms of MS. Roche today announced 96-week results from a Phase II study of ocrelizumab in patients with relapsing-remitting multiple ...

Roche reports positive study of Herceptin given by subcutaneous injection

Phase III study of a quicker route of administration shows comparable results to intravenous Herceptin. Roche today announced that the Phase III HannaH study demonstrated comparable efficacy of a ...

Roche signs definitive agreement to acquire Anadys Pharmaceuticals

Roche and Anadys Pharmaceuticals, Inc. (NASDAQ: ANDS) today announced that the two companies have entered into a definitive merger agreement for Roche to fully acquire Anadys at a price of USD 3.70 ...

Roche signs definitive agreement to acquire Anadys Pharmaceuticals

Roche posts solid sales performance in first nine months, achieves significant progress with personalised healthcare approaches

Group sales rise 2% at CER (-12% in Swiss francs; +7% in US dollars), excluding Tamiflu; Significant foreign exchange impact of -13% due to appreciation of Swiss franc; overall Group sales at 31.5 ...

Roche Licenses Nanopore Sequencing Technologies from Arizona State University and Columbia University for Rapid, Affordable DNA Sequencing

Roche and Arizona Technology Enterprises announced today an agreement to license several technologies developed by Dr. Stuart Lindsay at the Biodesign Institute at Arizona State University and Dr. ...

Study shows that Roche's investigational drug for Alzheimer's disease removes amyloid plaques from the brain

Roche today announced the publication of a study demonstrating that its monoclonal antibody gantenerumab removes amyloid plaques from the brain of patients with Alzheimer’s disease. The study ...

Roche NimbleGen Announces New Pre-capture Multiplexing for Target Enrichment Technology in Sequencing

With the decreasing cost and increasing throughput of sequencing, researchers require a high-performance, cost-effective sample preparation pipeline for targeted sequencing. To enable researchers to ...

Roche Redefines Global Coagulation Diagnostics The market leader of in vitro diagnostics heralds new era

With a number of industry firsts and innovative applications for early disease detection and monitoring, including a market leadership position in point of care coagulation management, Roche is now ...

Roche wins first major public tender in Europe to screen women for cervical cancer with its Human Papillomavirus test

Roche announced today that it has been awarded an exclusive contract by Karolinska University Hospital in Stockholm, Sweden, to provide a diagnostic tool for primary screening of Human Papillomavirus ...

Roche receives clearance from the U.S. Food and Drug Administration for new generation of Accu-Chek Aviva Plus Test Strips for people with diabetes

Roche announced today that it has received clearance from the U.S. Food and Drug Administration (FDA) for its Accu-Chek Aviva Plus test system.

Roche's investigational medicine T-DM1 shows improvement in progression-free survival compared to standard of care in HER2-positive metastatic breast cancer

Roche today announced the results of the Phase II study TDM4450g in patients with previously untreated HER2-positive metastatic breast cancer (mBC).

Roche's Avastin receives positive opinion from European authority for the treatment of women with newly diagnosed advanced ovarian cancer

Roche announced today that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the use of Avastin in combination with standard chemotherapy (carboplatin and ...

Roche Researchers Sequence Complete Genome of Cynomolgus Monkey and Develop Novel Gene Expression Microarray for Drug Safety Assessment

A team of researchers from Roche, including scientists from Roche Pharma Research and Early Development and Roche NimbleGen, reported in Genome Research that they have generated the first draft ...

First website focusing on early-stage Alzheimer's disease launches on World Alzheimer's Day

Roche today announced the launch of a new website, www.earlysymptomsalzheimers.com, designed to provide healthcare professionals, patients and caregivers with information about early-stage ...

Roche highlights data that demonstrate a range of new approaches to target breast, skin and lung cancers at 2011 European Multidisciplinary Cancer Congress

Roche today announced that encouraging data on its investigational and approved medicines will be presented at the 2011 European Multidisciplinary Cancer Congress in Stockholm being held 23-27 ...

Roche's xCELLigence System Monitors Beating Periodicity of Stem Cell Derived Cardiomyocytes in Preclinical Safety Assessment

Cardiac toxicity is a major concern in drug development and it is imperative that clinical candidates are thoroughly tested for adverse effects earlier in the drug discovery process. In a new ...

Roche named Dow Jones Sustainability Index leader in healthcare for third consecutive year

Reinforces commitment to creating long-term value for all stakeholders. Roche announced today that it has been recognized as the most sustainable healthcare company globally in the Dow Jones ...

Erasmus University Medical Centre in Rotterdam Adopts Automated Target Enrichment Solution from Roche NimbleGen and Caliper Life Sciences for 3,000 Sample Exome Study

The Genetic Laboratory of the Department of Internal Medicine at Erasmus University Medical Centre in Rotterdam has adopted the combined automated target enrichment solution from Roche and Caliper ...

Roche and Evotec agree to develop compound that could slow the progression of Alzheimer's disease

Roche Launches Cedex Bio Bioprocess Analyzer for Reliable Metabolite Profiling and Substrate Analysis in Biotherapeutics Manufacturing

A vast majority of biotherapeutics are manufactured in either bacterial or mammalian expression systems. Metabolite profiling and substrate analysis during the fermentation process is critical to ...

Roche's Tarceva receives European approval for first-line use in a genetically distinct type of lung cancer

Personalized approach to cancer medicine allows doctors to identify lung cancer patients who benefit from early treatment with Tarceva. Roche announced today that the European Commission has approved ...

The Roy J. Carver Center for Genomics (CCG) Achieves Certified Service Provider status for Roche NimbleGen microarrays

In May 2011, The University of Iowa, Roy J. Carver Center for Genomics (CCG), entered into an agreement with Roche NimbleGen to provide microarray services through the Roche NimbleGen Certified ...

Medicinal Genomics Sequences the Cannabis Genome Using Roche's GS FLX+ System

Medicinal Genomics, a private company headquartered in Marblehead, Mass., USA and the Netherlands, announced today that it has sequenced the entire genomes of Cannabis sativa and Cannabis indica, ...

Roche and PerkinElmer Enter into New Agreement for Distribution of NimbleGen CGX Cytogenetics Array Workflow

Roche and PerkinElmer today announced a new supply agreement for distribution of the NimbleGen CGX microarray workflow, for use in constitutional disease research.

FDA approves Zelboraf (vemurafenib) and companion diagnostic for BRAF mutation-positive metastatic melanoma, a deadly form of skin cancer

Roche today announced that the U.S. Food and Drug Administration (FDA) approved Zelboraf (vemurafenib) for the treatment of BRAF V600E mutation-positive, inoperable or metastatic melanoma, as ...

Researchers Decode Genome of Atlantic Cod Using 454 Sequencing Systems

In a study published online this week in Nature, an international team of researchers report the first complete sequence of the Atlantic cod genome and an unexpected discovery of the unique immune ...

Roche's investigational treatment for asthma met its primary endpoint in a phase II study

Roche today announced that a phase II study of its investigational treatment lebrikizumab, a humanized monoclonal antibody designed to block interleukin-13 (IL-13) cytokine, met its primary endpoint. ...

Roche's RoACTEMRA approved in Europe for children living with a rare and severe form of arthritis

Medicine offers new treatment option for Systemic Juvenile Idiopathic Arthritis (sJIA). Roche announced today that the European Commission has approved the use of RoACTEMRA (tocilizumab) for the ...

Roche's xCELLigence MP Instrument Used in the First Human Kinome Screen for Dynamic RNA Inhibitor Phenotypes during Cell Proliferation

RNA interference studies are a powerful technology for high-throughput screening. However, endpoint analyses only provide a snapshot of the analyzed cellular phenotype, as it is not possible to ...

„Roche Continents“ at the Salzburg Festival celebrates its five-year anniversary

Roche and the Salzburg Festival are celebrating the fifth- anniversary of their collaboration this year. Once again, as in the past years of cooperation, students of the sciences, art and music of 34 ...

cobas b 123 POC system - Blood gas analyzer from Roche awarded gold and “red” in medical design excellence

Roche is honored with the Gold Medical Design Excellence Award and Red Dot Design Award for the cobas b 123 POC system. The award ceremonies were held in New York in June for the Medical Design ...

Roche to provide HIV/AIDS tests for Early Infant Diagnosis in South Africa

Early testing helps reduce the impact of HIV on infants. Roche announced today that it has been awarded an exclusive contract by the National Health Laboratory Services (NHLS) in South Africa for ...

Roche's Tarceva gains positive CHMP opinion for first-line use in genetically distinct type of lung cancer

Roche announced today that the Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion in the EU supporting earlier, frontline use of Tarceva (erlotinib) in people with a ...

Roche's xCELLigence RTCA Cardio Instrument Used to Estimate the Risk of Drug-induced Proarrhythmia in Human Induced Pluripotent Stem Cell Derived Cardiomyocytes

Cardiotoxicity, which results when drugs adversely affect the heart, explains why roughly one third of new pharmaceuticals are withdrawn from the market and why many compounds fail in late-stage ...

Roche on track – full year earnings outlook increased

Group sales stable in local currencies. Excluding Tamiflu, Group sales up 2% and Pharmaceuticals Division sales up 1%; Diagnostics Division sales up 5%; on track to meet full-year guidance.

Roche's Cellavista System Performs Cell Analytics for a Novel Automated High Throughput Cell Culture Platform for Regenerative Medicine

Regenerative medicine is dependent on advances in tissue engineering, biochemistry and applied bioengineering to develop and produce cells and cell-based products that regenerate or repair damaged ...

Roche acquires mtm laboratories AG, expanding offering in cervical cancer testing

Roche announced today that it has signed an agreement under which it will acquire 100 percent of mtm laboratories AG (mtm), a privately-held company based in Heidelberg, Germany.

Pertuzumab combined with Herceptin and chemotherapy significantly extended the time people with HER2-positive metastatic breast cancer lived without their disease getting worse

Roche today announced that CLEOPATRA, a pivotal Phase III study, met its primary endpoint.

Roche Announces Thomas Schinecker as New President of 454 Life Sciences

454 Life Sciences, a center of excellence of Roche's business unit Applied Science, and developer of the innovative GS Junior and GS FLX+ Systems for high-throughput DNA sequencing, announced that ...

Roche NimbleGen and Caliper Collaborate to Offer Automated Target Enrichment Pipeline Solution for Next-Generation Sequencing

Roche and Caliper Life Sciences, Inc. today announced a co-marketing agreement for the development and optimization of automated protocols for the NimbleGen SeqCap EZ Library solution-based capture ...

Roche Applied Science Launches the Ultracompact LightCycler Nano System Worldwide

With “Size: Reduced. Fun: Amplified.”, Roche Applied Science launched its new real-time PCR system on June 27th, 2011. The small, silent, sleek LightCycler Nano Instrument supports state-of-the-art ...

Roche’s Avastin receives broader EU label for women with metastatic breast cancer

Expanded label allows combination with Xeloda or paclitaxel in first-line setting. Roche announced today that the European Commission has extended the existing Avastin (bevacizumab) metastatic breast ...

Roche provides update from FDA hearing on Avastin for metastatic breast cancer

FDA Commissioner to Make Final Decision at a Later Date. Roche announced today that, during a U.S. Food and Drug Administration (FDA) hearing on Wednesday, the FDA’s Oncologic Drugs Advisory ...

High throughput EHEC Pathogen Examination of Stool Samples using Roche´s MagNA Pure 96 and LightCycler Systems

During the last weeks, there has been a significant increase in the number of cases of bloody diarrhea associated with hemolytic-uremic syndrome (HUS) caused by enterohaemorrhagic Escherichia coli ...

Roche Launches GS FLX+ System Offering High-Quality, Sanger-like Reads with the Power of Next-Generation Throughput

454 Life Sciences, a Roche Company (SIX: RO, ROG; OTCQX: RHHBY), announced today the launch and immediate availability of the new GS FLX+ System, an instrument capable of generating extra-long ...

Roche and Evotec to jointly develop biomarkers in oncology

Roche and Evotec AG today announced a collaboration in novel protein-activity based biomarkers for Roche’s oncology drugs under development.

Roche sets up R&D Institute in France to foster collaborative translational research

Roche announced today the launch of a new R&D Institute in France under the lead of the company's Pharma Research and Early Development (pRED) unit.

Roche Diagnostics supports European Union's DETECTIVE Project to reduce Animal Testing

The xCELLigence RTCA System of Roche is being used in the European Union’s DETECTIVE ("Detection of endpoints and biomarkers for repeated dose toxicity using in vitro systems”) Project, a joint study ...

15 years of growth above the market

The Roche Diagnostics Division is celebrating the 15th anniversary of its Elecsys® platform, the company’s key driver in immunochemistry. Elecsys continually sets new standards in immunodiagnostics ...

Pivotal study showed vismodegib helped shrink tumours or heal lesions in people with rare form of advanced skin cancer

Roche announced today that a pivotal Phase II study with vismodegib showed positive results in people with advanced basal cell carcinoma (BCC) for whom surgery is considered inappropriate.

Roche´s xCELLigence RTCA HT System: Fully-automated Measurement of Therapeutic Targets` Cellular Activity

High throughput, real time impedance-based secondary screening of Ox1 GPCR hits. Label-free technologies have entered the stage of cellular drug discovery and high-throughput screening (HTS). For the ...

Roche Children's Walk 2011: Employees worldwide walk on the same day to raise awareness for vulnerable children in Malawi and around the world

Every year since 2003 Roche employees raise awareness for children in need by walking to collect donations for day-care centres in Malawi and children’s charities in their own countries.

Deadly E. Coli Strain Sequenced with Roche GS Junior System by HPA Scientists - Provides Community Most Complete Assembly to Date

The deadly E. coli O104 strain that has killed dozens and hospitalized thousands across Europe has been sequenced using 454 Life Sciences' benchtop GS Junior sequencing system to generate the "most ...

Data Quality Meets Enjoyment: Roche´s New Small LightCycler System Presented at Real-Time PCR Symposium in Prague

At the “Developments in Real-Time PCR” Symposium in Prague, June 13th – 17th, Roche officially presented the latest addition to the company’s real-time PCR portfolio of LightCycler instruments. The ...

Agreement with Roche gives UCLA Stem Cell and Cancer Researchers Early Access to Leading-edge Technologies for the Advancement of Medical Research

An agreement between UCLA and Roche will provide stem cell and cancer researchers with leading-edge technologies that will drive research capabilities and further the understanding of complex disease.

Roche announces vemurafenib improved survival in people with metastatic melanoma who have BRAF V600 mutations

Roche’s Personalised Healthcare approach demonstrated through vemurafenib and its investigational companion diagnostic, Roche’s cobas 4800 BRAF V600 Mutation Test. Roche today announced that a Phase ...

Roche announces data to show Avastin based regimen halved the risk of disease getting worse in women with recurrent ovarian cancer

Phase III OCEANS results add to the growing body of evidence supporting Avastin’s potential role in ovarian cancer. Roche today announced results from OCEANS, a phase III study evaluating Avastin ...

Tarceva nearly doubled the time people with a genetically distinct type of lung cancer lived without their disease getting worse

Roche today announced results of EURTAC, the first Phase III study with Tarceva (erlotinib) in Western patients with a genetically distinct type of advanced non-small cell lung cancer (NSCLC). EURTAC ...

Roche enters collaboration with Bristol-Myers Squibb to study combination therapy with vemurafenib and ipilimumab in advanced skin cancer

Roche today announced that it has entered into a clinical collaboration agreement with Bristol-Myers Squibb Company (NYSE:BMY) to investigate the combination of vemurafenib with Bristol-Myers ...

Roche enters collaboration with Bristol-Myers Squibb to study combination therapy with vemurafenib and ipilimumab in advanced skin cancer

Roche Applied Science and TIB Molbiol offer Assay Solution for Rapid EHEC Identification

With the recent outbreak in Europe of Enterohaemorrhagic Escherichia coli (EHEC), Roche Applied Science and TIB Molbiol are providing scientists with complementary technologies that can be used for ...

Roche signs exclusive agreement with IT-IS Life Sciences Ltd on the new LightCycler Nano Instrument for low-throughput qPCR market

Roche Applied Science has signed a worldwide exclusive OEM agreement with IT-IS Life Sciences Ltd for the distribution of the new LightCycler Nano Instrument, which will complete the company's ...

RoACTEMRA could change the current standard of treatment for people living with rheumatoid arthritis

New study confirms RoACTEMRA is effective when used on its own for people who do not respond to methotrexate. Roche today announced new data from the ACT-RAY study, presented at the European League ...

454 Sequencing Systems Aid in Discovery of Novel Canine Hepatitis C Virus

In a study published online this week in the Proceedings of the National Academy of Sciences, researchers report the use of high-throughput sequencing technology to identify a novel hepatitis C virus ...

MetMAb in combination with Tarceva doubled the time people with lung cancer lived without their disease getting worse

Roche’s investigational personalised medicine showed promising final Phase II results in people with a form of lung cancer

Roche to present significant progress in advanced skin, lung and ovarian cancers at ASCO

Progress in advanced skin and lung cancers through personalised healthcare. New Phase III data for Avastin in ovarian cancer to be presented

Roche and Merck Establish Strategic Agreements in Fight Against Chronic Hepatitis C

Roche announced today that it has entered into agreements with Merck, known as MSD outside the United States, through their respective subsidiaries, to improve the treatment, diagnosis and awareness ...

Roche and Merck Establish Strategic Agreements in Fight Against Chronic Hepatitis C

Roche Diagnostics launches Vitamin D total assay

With the launch of the Vitamin D total assay for the Elecsys analyzers and cobas modular platforms on May 13 in Europe as well as other regions including the CE mark Roche validates its leading ...

AgenoLAB Broadens Service Offering for Drug Development with Roche's RTCA Cardio Instrument

AgenoLAB, the Stuttgart-based service provider, is the first company in Germany to expand its service offering with the latest cell analysis technology from Roche. The company will use the RTCA ...

New drug applications submitted in the United States and Europe for vemurafenib in advanced skin cancer

Roche today announced that the company submitted a New Drug Application for vemurafenib (RG7204, PLX4032) to the U.S. Food and Drug Administration (FDA) and a Marketing Authorization Application to ...

Electrical Impedance as a Novel Biomarker of Myotube Atrophy and Hypertrophy - Measured with Roche's xCELLigence System

Tracking physiological changes in skeletal muscle thickness is a direct and unbiased approach in screening therapeutic compounds that prevent skeletal muscle atrophy or induce hypertrophy. In a ...

BaseClear BV Certified to Provide NimbleGen Sequence Capture Services in The Netherlands

Roche NimbleGen, a Roche Company announced today that the Netherlands-based genomic service provider BaseClear BV has officially joined the Roche NimbleGen Certified Service Provider (CSP) Program. ...

Roche's RTCA HT Instrument Adapts Real-Time Cell Analysis to a High-Throughput Format

The new xCELLigence RTCA HT Instrument from Roche rounds out the Diagnostics Applied Science's portfolio in real-time cell analysis with a high-throughput product.

FDA Approves Roche's HPV Test for Identifying Women at Highest Risk for Cervical Cancer

Roche announced today that the US Food and Drug Administration (FDA) has approved the cobas HPV (Human Papillomavirus) Test which identifies women at highest risk for developing cervical cancer. This ...

Ambry Genetics Adds Certification of Roche NimbleGen CGH, DNA Methylation, Gene Expression, and ChIP-chip to Service Portfolio

Roche NimbleGen announces that Southern California (Aliso Viejo) based genomic services provider Ambry Genetics has officially become a Certified Service Provider (CSP) for NimbleGen Comparative ...

FDA approves Actemra for the treatment of Systemic Juvenile Idiopathic Arthritis (SJIA)

Medicine offers a new option for children living with a rare and severe form of arthritis. Roche today announced that the United States (U.S.) Food and Drug Administration (FDA) approved Actemra for ...

Roche gains positive CHMP opinion for the combination of Avastin with Xeloda as a first-line treatment for metastatic breast cancer in Europe

Approval would allow combination of Avastin with paclitaxel or Xeloda, offering more choice to physicians and patients

Is lunar dust harmful to humans?

Roche’s xCELLigence System used to investigate effects of lunar and Martian dust on mammalian skin. Exposure to lunar dust during the Apollo missions resulted in reports of ocular, respiratory and ...

Roche Group’s first-quarter 2011 sales on track for full-year targets – positive results in seven key clinical trials

Group sales stable in local currencies (-9% in Swiss francs; +2% in US dollars) at 11.1 billion Swiss francs in first three months of 2011. Excluding Tamiflu, Group sales rise 2% (-7% in Swiss ...

Roche and Lonza enter into MycoTOOL Distribution Agreement for Rapid Mycoplasma Testing Solutions

Roche and Lonza announced today that they have entered into a co-exclusive distribution agreement for the commercialization of Roche’s MycoTOOL mycoplasma PCR assays. MycoTOOL detection kits are now ...

MIT's Koch Institute to use Roche LightCycler 480 System to help advance cancer research

System used for detection of genetic material will help scientists explore molecular basis of diseases. Roche announced today that the David H. Koch Institute for Integrative Cancer Research at MIT ...

Roche announces positive Phase II results for trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer

Roche today announced topline results of its first randomized trial of trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer. The Phase II trial, known as TDM4450g, compared ...

Roche Joins in Spanish Research Cooperation for Personalized Treatment of Hepatitis B and C

Roche Diagnostics is cooperating with the Spanish Vall d’Hebron Institute of Research (VHIR), the Networking Biomedical Research Centre in Liver and Digestive Diseases (CIBEREHD), and the software ...

Roche and NuGEN Technologies Develop Whole Transcriptome Profiling Solution for 454 Sequencing Systems

Roche and NuGEN Technologies to co-promote NuGEN’s Ovation RNA-Seq System with the GS FLX and GS Junior Systems to enable whole transcriptome profiling with low abundance RNA samples. 454 Life ...

Roche Diagnostics Announces the Appointment of Robert Yates as New Head of Roche Applied Science

Roche Diagnostics announced today that effective from April 1, Robert Yates has been appointed as new Head of Roche Applied Science. He succeeds Manfred Baier, who will be retiring from Roche at the ...

Roche's test for Cytomegalovirus is approved in Europe

Roche announced today that its Cytomegalovirus (CMV) test is now commercially available in Europe. CMV viral load testing helps physicians manage immunocompromised patients at risk of CMV disease, ...

Roche Introduces Next-Generation HLA Typing Solution for 454 Sequencing Systems

454 Life Sciences, a Roche Company, announced today the launch and immediate availability of the new GS GType HLA Primer Sets for high- and medium-resolution genotyping of class I and class II loci ...

ATLAS Biolabs achieves Roche NimbleGen Certification for solution-based SeqCap EZ enrichment

Roche NimbleGen announces that ATLAS Biolabs GmbH, located in Berlin, Germany, has passed the certification process to qualify as a Roche NimbleGen Certified Service Provider (CSP) for SeqCap EZ ...

A life sciences renaissance: 125th peer-reviewed publication enabled by xCELLigence System

To date, more than 125 peer-reviewed studies using Roche's xCELLigence System have been published, spanning a diverse group of applications, including cell invasion and migration of cancer cells, ...

Roche announces positive pivotal Phase II results for Hedgehog Pathway Inhibitor in advanced basal cell carcinoma

Roche today announced that a pivotal Phase II clinical study of its investigational Hedgehog Pathway Inhibitor, vismodegib (RG3616/GDC-0449), showed positive results in people with advanced basal ...

Research Study Characterized Analytical Performance and Clinical Potential of Roche Flu Test

The availability of suitable diagnostic tools for identifying infected individuals is crucial for precise treatment in infectious diseases. The appearance of a novel pandemic human strain of ...

Using Roche's CASY Cell Counter and Analyzer for proliferation and viability measurement in cancer studies

In a recent study, Prokop et al. used the CASY Cell Counter and Analyzer from Roche Applied Science to identify the specific anticancer properties of a therapeutic substance in Burkitt-like lymphoma ...

Roche acquires PVT to strengthen laboratory automation in clinical diagnostics

Roche announced today the acquisition of PVT Probenverteiltechnik GmbH based in Waiblingen, Germany and of PVT Lab Systems, LLC based in Atlanta, Georgia, USA. PVT is a global market leader in ...

Roche and RainDance Technologies Join Forces in Targeted Sequencing to Advance ADME Research

RainDance Technologies, Inc., and 454 Life Sciences, a Roche Company, today announced collaboration for the development and commercialization of a targeted next-generation sequencing (NGS) solution ...

European Commission continues to support Avastin in combination with paclitaxel as an effective treatment option for women with metastatic breast cancer

Roche announced today that the European Commission confirmed that Avastin (bevacizumab) in combination with paclitaxel will remain a treatment option for women with metastatic breast cancer in Europe.

Roche Annual General Meeting: dividend raised by 10%

Roche's Annual General Meeting, which was held today in Basel, has approved all of the Board of Directors' proposals. The 818 shareholders in attendance, representing 142,963,212 or 89.4% of a total ...

Third phase III study of Avastin-based regimen met primary endpoint in ovarian cancer

Roche announced today that OCEANS, a phase III study evaluating Avastin (bevacizumab) in combination with chemotherapy (carboplatin and gemcitabine) followed by continued use of Avastin alone until ...

First Duplex Test for Parvovirus B19 and Hepatitis A Virus Now Available in the US

Roche announced today that the cobas TaqScreen DPX Test for use on the cobas s 201 system is now available in the US. It is the first commercial test to quantify parvovirus B19 and detect hepatitis A ...

Solid overall results

Mid-single digit sales growth in local currencies excluding Tamiflu - Strong profit growth - Promising late stage pharmaceutical pipeline of twelve new molecular entities

FDA approves Rituxan/MabThera for first-line maintenance use in follicular lymphoma

Roche today announced that the U.S. Food and Drug Administration (FDA) approved Rituxan/MabThera (rituximab) as a maintenance treatment for patients with advanced follicular lymphoma who responded to ...

Early successful readout of Tarceva study in a distinct form of lung cancer

Roche today announced that an independent data monitoring committee has recommended that the phase III EURTAC study be stopped early because the study met its primary endpoint. At a planned interim ...

Roche personalized investigational medicine shows survival benefit in advanced skin cancer

Roche today announced that BRIM3, a Phase III clinical study of RG7204 (PLX4032), met its co-primary endpoints showing a significant survival benefit in people with previously untreated BRAF V600 ...

454 Life Sciences, University of Florida, and DOE JGI Sequence Sweet Orange Genome, Publish Annotated Assembly to Public Database

Researchers from the International Citrus Genomics Consortium announced this weekend at the Plant and Animal Genome (PAG) XIX conference in San Diego, California the availability of the sequence ...

Changes to the Roche Corporate Executive Committee

Erich Hunziker (born 1953), Chief Financial Officer, Chief Information Officer and Deputy Head of the Corporate Executive Committee has decided to retire from Roche at the end of March 2011 and plans ...

FDA grants supplemental approval for ACTEMRA

Roche today announced that the United States Food and Drug Administration has extended the ACTEMRA label to include inhibition and slowing of structural joint damage, improvement of physical ...